Treatment with ZYKADIA may cause GI Adverse Reactions, Hepatic and Embryo-fetal Toxicities, Interstitial Lung Disease/Pneumonitis, QTc Interval Prolongation, Hyperglycemia, Bradycardia, Pancreatiti...
View information for patients starting treatment with ZYKADIA.
Help your eligible patients access ZYKADIA by filling out the personal information and insurance sections of this form.
ZYKADIA is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
IMPORTANT SAFETY INFORMATION
Gastrointestinal Adverse Reactions
Interstitial Lung Disease/Pneumonitis
QTc Interval Prolongation
Please see full Prescribing Information.